Spots Global Cancer Trial Database for octreotide lar
Every month we try and update this database with for octreotide lar cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| 5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors | NCT00953394 | Neuroendocrine ... | continuous 5 fl... | 18 Years - | University of Turin, Italy | |
| Real-world Study on Adjuvant Octreotide Therapy in pNETs | NCT06080204 | Pancreatic Neur... | Octreotide LAR | 18 Years - 80 Years | Changhai Hospital | |
| A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET | NCT05050942 | Gastro-enteropa... | CAM2029 Octreotide LAR Lanreotide ATG | 18 Years - | Camurus AB | |
| Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis | NCT00332696 | Peritoneal Neop... Intestinal Obst... Carcinomatosis | Octreotide LAR Octreotide (Imm... methylprednisol... Placebo | 18 Years - | Novartis | |
| A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours | NCT01578239 | Carcinoid Tumor... Neuroendocrine ... | Octreotide LAR 177Lu-DOTA0-Tyr... | 18 Years - | Advanced Accelerator Applications | |
| A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs | NCT05459844 | Neuroendocrine ... | Lutetium[177Lu]... Octreotide LAR | 18 Years - | Sinotau Pharmaceutical Group | |
| Octreotide LAR as Maintenance Treatment for Patients With NEC | NCT02409849 | Gastro-entero-p... Esophageal Neur... | Octreotide lar | - | Peking University | |
| Real-world Study on Adjuvant Octreotide Therapy in pNETs | NCT06080204 | Pancreatic Neur... | Octreotide LAR | 18 Years - 80 Years | Changhai Hospital | |
| RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma | NCT00113360 | Neuroendocrine ... Islet Cell Carc... | RAD001 Octreotide Depo... | 18 Years - | M.D. Anderson Cancer Center | |
| Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET | NCT01567488 | Gastrointestina... | Everolimus octreotide LAR | 18 Years - | Grupo Espanol de Tumores Neuroendocrinos | |
| Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis | NCT00332696 | Peritoneal Neop... Intestinal Obst... Carcinomatosis | Octreotide LAR Octreotide (Imm... methylprednisol... Placebo | 18 Years - | Novartis | |
| Surgical Debulking of Pituitary Adenomas | NCT01371643 | Pituitary Adeno... | Octreotide LAR transsphenoidal... | 18 Years - | NYU Langone Health | |
| Octreotide LAR as Maintenance Treatment for Patients With NEC | NCT02409849 | Gastro-entero-p... Esophageal Neur... | Octreotide lar | - | Peking University | |
| A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours | NCT01578239 | Carcinoid Tumor... Neuroendocrine ... | Octreotide LAR 177Lu-DOTA0-Tyr... | 18 Years - | Advanced Accelerator Applications | |
| Real-world Study on Adjuvant Octreotide Therapy in pNETs | NCT06080204 | Pancreatic Neur... | Octreotide LAR | 18 Years - 80 Years | Changhai Hospital | |
| Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients | NCT00166725 | Prostate Cancer | Octreotide LAR | 18 Years - 80 Years | Novartis | |
| Surgical Debulking of Pituitary Adenomas | NCT01371643 | Pituitary Adeno... | Octreotide LAR transsphenoidal... | 18 Years - | NYU Langone Health | |
| A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs | NCT05459844 | Neuroendocrine ... | Lutetium[177Lu]... Octreotide LAR | 18 Years - | Sinotau Pharmaceutical Group | |
| Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients | NCT00166725 | Prostate Cancer | Octreotide LAR | 18 Years - 80 Years | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
